Clinical reports on Ganoderma lucidum for adjuvant treatment on diabetes mellitus
- Feb 23, 2017 -
At the 2002 International Symposium on Ganoderma lucidum in Shanghai, China, a clinical report showed that Ganoderma lucidum capsules(0.25g per capsulecontaining 70% of Ganoderma lucidum fruiting body extract, 20% of Ganoderma lucidum spores and 10% of a filler) significantly enhanced the efficacy of conventional oral hypoglycemic drug on the Type 2 diabetes patients in the Drug-Only Group and those of the 100 patients in the Drug with Ganoderma lucidum+Group before the trial. After the treatment, the FBG among the Ganoderma lucidum+Drug patients decreased significantly, and they also significantly differed from those of the Drug-Only patients. On the other hand, there were groups (Table 7-1). Meanwhile， by incorporation of Ganoderma lucidum capsules in the drug treatment, a significant effect on alleviating dizziness, thirst, fatigue, body aches and weak legs was observed among the patients.
Zhang,C.Y. and Li, Y.M. Clinical investigation of Green Valley Ganoderma capsule on Type 2 diabetes mellitus. In “Ganoderma : Genetics, Chemistry, Phadmacology and Threapeutics” Z.B. Lin ed. Beijing Medical University Press， Beijing, 2002:194-198
Another study evaluated the efficacy of Ganopoly(Polysaccharides extracted from Ganoderma ducidum)in 71 Type 2 diabetes mellitus patients. There 18-year-old patients with normal electrocardiogram were diagnosed with the disease longer than 3 months and habe never received insulin for treatment. Those who were never treated with sulfonylurea had a fasting plasma glucose(FPG) ranging from 8.9 to 16.7 mmol/L, and those sulfonylurea-treated patients had an FPG of 10mmol/L prior to stopping the drug treatment. All participating patients were randomly divided into Treatment and Control Groups. The patients were given orally 1800mg Ganopoly or a placebo, 3 times daily for 12weeks. After fasting, glycosylated hemoglobin, plasma glucose, insulin and C-peptide were determined for the patients before and after meal. The results showed that Ganopoly significantly decreased the average Hba1c in the patients, from 8.4 before the treatment to 7.6% at the end of the 12th week. Significant changes on FPG and post-prandial plasma glucose(PPG) paralleled those on HbA1c, decreasing from 13.6 to 11.8 mmol/L. In contrast, there were either no changes or slight increases in patients in the Control group who received placebo. The insulin and C-peptide levels of the patients at fasting or 2 hours after a meal, also showed significant difference between the two groups. All patients appeared to have no apparent side effects in taking Ganopoly during the course of the trial. The study concluded that Ganopoly could be effectively applied for treating Type 2 diabetes mellitus patients.
Gao, Y., Lan, J., X., Te, J. and Zhou, S. A phase study of organic reishi. Lloyd extract in patients with Type 2 diabetes mellitus. Int J Med Mush. 2004, 6:33-9.